A strategic therapeutic alternative is the modulation of platelet-secreted alarmins, such as high mobility group box protein 1 (HMGB1) and Cyclophilin A. HMGB1 and Cyclophilin A are molecules that alarm and amplify immune responses, playing significant roles in endothelial dysfunction, leukocyte recruitment, and NETosis [78]. Here, HMGB1 is linked to endothelial dysfunction.